AbCellera Biologics (ABCL) Competitors $2.83 +0.04 (+1.43%) (As of 09:08 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ABCL vs. MLTX, EWTX, JANX, XENE, FOLD, MRUS, ACAD, MOR, ZLAB, and VERAShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include MoonLake Immunotherapeutics (MLTX), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Zai Lab (ZLAB), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry. AbCellera Biologics vs. MoonLake Immunotherapeutics Edgewise Therapeutics Janux Therapeutics Xenon Pharmaceuticals Amicus Therapeutics Merus ACADIA Pharmaceuticals MorphoSys Zai Lab Vera Therapeutics AbCellera Biologics (NASDAQ:ABCL) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Do analysts prefer ABCL or MLTX? AbCellera Biologics currently has a consensus price target of $8.67, suggesting a potential upside of 210.63%. MoonLake Immunotherapeutics has a consensus price target of $81.43, suggesting a potential upside of 44.63%. Given AbCellera Biologics' higher probable upside, equities research analysts plainly believe AbCellera Biologics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Do institutionals and insiders believe in ABCL or MLTX? 61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 28.0% of AbCellera Biologics shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to ABCL or MLTX? In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 7 mentions for MoonLake Immunotherapeutics and 2 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.26 beat MoonLake Immunotherapeutics' score of 0.77 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ABCL or MLTX? MoonLake Immunotherapeutics received 9 more outperform votes than AbCellera Biologics when rated by MarketBeat users. Likewise, 80.52% of users gave MoonLake Immunotherapeutics an outperform vote while only 75.71% of users gave AbCellera Biologics an outperform vote. CompanyUnderperformOutperformAbCellera BiologicsOutperform Votes5375.71% Underperform Votes1724.29% MoonLake ImmunotherapeuticsOutperform Votes6280.52% Underperform Votes1519.48% Which has more risk and volatility, ABCL or MLTX? AbCellera Biologics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Which has higher valuation and earnings, ABCL or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than AbCellera Biologics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$32.96M25.00-$146.40M-$0.61-4.57MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.29-43.64 Is ABCL or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. MoonLake Immunotherapeutics' return on equity of -15.54% beat AbCellera Biologics' return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-533.32% -15.73% -12.22% MoonLake Immunotherapeutics N/A -15.54%-15.09% SummaryMoonLake Immunotherapeutics beats AbCellera Biologics on 11 of the 18 factors compared between the two stocks. Ad Diversified Trading InstituteGenesis leading the smart algo revolution?I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!You’ll want to see what I’ve put on this page right here Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$824.07M$6.87B$5.20B$9.31BDividend YieldN/A3.06%4.80%4.06%P/E Ratio-4.5710.75128.1117.53Price / Sales25.00287.461,260.62139.54Price / CashN/A56.6541.3637.95Price / Book0.705.394.894.92Net Income-$146.40M$152.04M$119.92M$225.78M7 Day Performance-4.12%-4.33%16.64%-1.56%1 Month Performance5.28%2.79%16.35%6.68%1 Year Performance-47.56%17.30%35.47%22.48% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.1812 of 5 stars$2.83+1.4%$8.67+206.2%-48.6%$835.89M$32.96M-4.64586MLTXMoonLake Immunotherapeutics1.7963 of 5 stars$52.07+1.4%$79.88+53.4%-7.2%$3.33BN/A-39.802News CoverageEWTXEdgewise Therapeutics2.8314 of 5 stars$34.97+26.6%$42.33+21.1%+313.9%$3.31BN/A-22.8560Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeJANXJanux Therapeutics3.6007 of 5 stars$62.25+1.9%$89.90+44.4%+474.8%$3.27B$13.05M-52.2330XENEXenon Pharmaceuticals2.7408 of 5 stars$41.15+2.7%$56.90+38.3%-0.3%$3.14B$9.43M-14.20251FOLDAmicus Therapeutics4.3924 of 5 stars$9.90+5.8%$16.88+70.5%-22.2%$2.96B$493.67M-28.71480Analyst DowngradeMRUSMerus2.9438 of 5 stars$42.84+0.0%$85.64+99.9%+77.9%$2.93B$43.95M-10.8437ACADACADIA Pharmaceuticals3.9301 of 5 stars$17.50+1.4%$25.60+46.3%-39.1%$2.91B$726.44M22.13510MORMorphoSys0.0818 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730ZLABZai Lab2.5215 of 5 stars$26.05-1.1%$55.00+111.1%-10.1%$2.83B$355.75M-9.512,175VERAVera Therapeutics3.5494 of 5 stars$44.53+1.1%$59.22+33.0%+174.4%$2.82BN/A-16.8840 Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Edgewise Therapeutics Competitors Janux Therapeutics Competitors Xenon Pharmaceuticals Competitors Amicus Therapeutics Competitors Merus Competitors ACADIA Pharmaceuticals Competitors MorphoSys Competitors Zai Lab Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABCL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABCL Stock Alerts